Changes in Beneficial Ownership · 4
Cognition Therapeutics, Inc.
CGTXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2618497-1_4seq1.xml
Filing details
- Report period
- 2026-06-17
- Issuer
- COGNITION THERAPEUTICS INC
- Issuer CIK
- 0001455365
- Trading symbol
- CGTX
Reporting owner 1
- Name
- RICHSTONE ELLEN B
- Reporting owner CIK
- 0001281526
- Relationship
- Director
- Address
- C/O COGNITION THERAPEUTICS INC, 2500 WESTCHESTER AVE., PURCHASE, NY, 10577
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-17 | A · Form 4 | 25,000[F1] | A | 0.00 | 83,500 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.↩ 1
Signature 1
- Signed
- /s/ John Brendan Doyle, Attorney-in-Fact
- Date
- 2026-06-22
Company context
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition Therapeutics continues to advance clinical research in its efforts to bring forth solutions that meet patients where they are and reduce caregiver burden. Learn more at cogrx.com.